/
HURA
$2.29+$0.13 (+6.02%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$137.6M
64M shares
52-week range
$0.41 – $3.90
54% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
20.34%
Hard to borrow
Price (6 mo)
Loading chart…
Change$-4.01
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $16.3K | $10.0K | $32.0K | $60.0K | $60.0K | $55.0K | $0 | $0 |
| Gross profit | −$16.3K | −$10.0K | −$32.0K | −$60.0K | −$60.0K | −$55.0K | $0 | $0 |
| Gross margin | — | — | — | — | — | — | — | — |
| R&D | $3.7M | $3.6M | $11.8M | $15.2M | $9.3M | $2.7M | $13.3M | $20.5M |
| Operating income | −$8.4M | −$8.1M | −$21.6M | −$22.7M | −$14.8M | −$8.5M | −$17.6M | −$31.8M |
| EBITDA | −$8.0M | −$9.1M | −$38.1M | −$22.0M | −$14.6M | −$8.3M | −$17.4M | −$29.4M |
| Net income | −$8.0M | −$9.1M | −$38.3M | −$22.7M | −$14.6M | −$8.3M | −$21.7M | −$30.1M |
| Net margin | — | — | — | — | — | — | — | — |
| EPS (diluted) | -5524.99 | -1532.00 | -2805.84 | -903.03 | -324.48 | -11.29 | -1.21 | -0.63 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $11M | $-0.56 | $-0.64–$-0.50 | 2 |
| 2027 | $34M | $-0.56 | $-0.61–$-0.51 | 2 |
| 2028 | $21M | $-0.55 | $-0.58–$-0.52 | 2 |
| 2029 | $66M | $-0.20 | $-0.20–$-0.20 | 1 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
TuHURA Biosciences, Inc. Common Stock
TuHURA Biosciences Inc is a phase 3 clinical stage immuno-oncology company with three distinct technologies focused on the development of novel therapeutics designed to overcome primary and acquired resistance to cancer immunotherapies. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. The company operates in one reportable segment, which includes all activities related to advancing therapies for cancer treatment.
www.tuhurabio.com- Employees
- 22
- IPO / List date
- Oct 18, 2024
- HQ
- TAMPA, FL
Held by traders on TradeandTell
No one on the platform currently holds HURA.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in HURA as of their last filing.
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2024-10-18 | 2-for-1 |
Recent trades on TradeandTell
No one on the platform has traded HURA yet.
